Trial Profile
Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Atoltivimab/maftivimab/odesivimab (Primary)
- Indications Ebola virus infections
- Focus Expanded access; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 10 Jul 2018 New trial record